

Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)

Technology appraisal guidance

Published: 17 May 2023

www.nice.org.uk/guidance/ta889

Contents

Advice.....	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma in adults. This is because Janssen withdrew its evidence submission for the appraisal. Janssen considers that the technology will not, at this time, be launched in the UK for treating this indication.

Information

If NHS organisations wish to consider ciltacabtagene autoleucel for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-5190-1

Accreditation

